Brief: Disc Medicine Announces Successful End Of Phase 2 Meeting With FDA For Bitopertin In Erythropoietic Protoporphyria

Disc Medicine

04/11/2024 13:31

Nov 4 (Reuters) - Disc Medicine Inc  IRON.O :
    * DISC MEDICINE ANNOUNCES SUCCESSFUL END OF PHASE 2 MEETING
WITH
FDA FOR BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA (EPP),
INCLUDING POTENTIAL FOR ACCELERATED APPROVAL
    * DISC MEDICINE INC - TO INITIATE APOLLO TRIAL BY MID-2025
    * DISC MEDICINE INC - FDA AGREES WITH ALL PROPOSED STUDY
PARAMETERS FOR BITOPERTIN

Source text:  ID:nGNX4b04fm 
Further company coverage:  IRON.O 

 (Reuters.Briefs@thomsonreuters.com)